In this study, we revealed that Gboxin arrested TMZ-sensitive and TMZ-R GBM cells in the G1 or S phase by decreasing CDK1 and CDK2 expression in a dose-dependent manner at the protein level. The gene discussed is CDK2; the disease is glioblastoma.